Jul. 24 at 4:35 PM
$ELTP $DJT $GME $PFE $JNJ
The SequestOx LegacyThe Technology: SequestOx is an immediate-release oxycodone formulation combined with sequestered naltrexone designed to prevent opioid abuse if capsules are crushed or dissolved The Strategic Pivot: Management deliberately shifted its core focus toward commercializing high-margin generic portfolios rather than relying on high-risk opioid novel pathways.
Financial BreakoutElite Pharmaceuticals recently reported robust growth for its fiscal year ended March 31, 2026:Revenue: Surged 77% to
$148.9 million from
$84 million in the previous year.Operating Income: Tripled, climbing 151% to
$49.1 million.Growth Drivers: Gains were heavily fueled by full-year sales of generic Lisdexamfetamine (generic Vyvanse) and successful in-house direct-label product rollouts.The Next Catalyst: The company recently submitted an Abbreviated New Drug Application (ANDA) for a mega-generic anticoagulant targeting a multi-billion dollar market space.
